Science-led biopharmaceutical company AstraZeneca Plc (STO:AZN) (LON:AZN) (NYSE:AZN) and pharmaceutical company MSD Inc (Merck & Co Inc in US and Canada) (NYSE:MRK) announced on Monday that a supplemental New Drug Application for Lynparza (olaparib) has been accepted and granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer (mCRPC) and deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations, who have progressed following prior treatment with a new hormonal agent.
Also, a Prescription Drug User Fee Act (PDUFA) date is set for the second quarter of 2020.
Reportedly, this Priority Review by the US Food and Drug Administration (FDA) is based on results from the phase III PROfound trial, which were presented during the Presidential Symposium at the 2019 European Society of Medical Oncology congress.
Results of the PROfound trial showed Lynparza significantly reduced the risk of disease progression or death by 66% based on a hazard ratio of 0.34 (p
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886